Publications by authors named "Arun Sendilnathan"

Claim this Profile
H
How anti-c in a D- patient prompted lifesaving work between a transfusion service and a blood center reference laboratory.
Gavin Patch, Joan Maurer, Arun Sendilnathan, Christine Leak, Elizabeth Nartowicz

Immunohematology· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story.
Rand Naffouje, Punita Grover, Hongyang Yu, Arun Sendilnathan, Kara Wolfe

Cancers (Basel)· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma.
Trisha Wise-Draper, Arun Sendilnathan, Sarah Palackdharry, Nicholas Pease, Julianne Qualtieri

Transl Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.
Rishi Agarwal, Arun Sendilnathan, Nabeela Iffat Siddiqi, Shuchi Gulati, Abhimanyu Ghose

J Gastrointest Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.
David M Gill, David D Stenehjem, Kinjal Parikh, Joseph Merriman, Arun Sendilnathan

Ecancermedicalscience· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic virotherapy for head and neck cancer: current research and future developments.
Akshiv Malhotra, Arun Sendilnathan, Matthew O Old, Trisha M Wise-Draper

Oncolytic Virother· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.
Elaine T Lam, Michael K K Wong, Neeraj Agarwal, Bruce G Redman, Theodore Logan, Arun Sendilnathan

J Immunother· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis